ACKRELL CAPITAL CHAPTERV_ Global Cannabis Regulation in 2013 by the Marihuana [sic] Medical Program Regulations (MMPR). The MMPR created a regu- latory framework under which individuals with a medical need could obtain dry cannabis flower from licensed commercial producers. Like the MMAR before it, the MMPR was held unconstitutional and was eventually replaced, this time in August 2016, by the currently effective Access to Cannabis for Medical Purposes Regulations (ACMPR). The ACMPR permits businesses licensed by Health Canada to commercially produce and distrib- ute cannabis flower, cannabis oil and cannabis starter materials, such as plants and seeds, to individuals with a medical recommendation from an authorized health care practitioner. The ACMPR also allows such individuals to produce a limited amount of cannabis for their own medical purposes, or to des- ignate another person (which may include Health Canada) to produce it for them. The ACMPR sets forth a comprehensive licensing and regulatory regime that addresses security of licensed production facilities, import and export permits, quality control measures and labeling requirements, and imposes limits on the amount of cannabis that can be produced and possessed by an individual. In April 2017, a proposed recreational law was introduced in the Canadian parliament; this legis- lation would allow adults to purchase cannabis from federally licensed producers and to possess and share cannabis with other adults. The proposed Cannabis Act would authorize the Canadian govern- ment to issue regulations for the administration and enforcement of the act and to issue licenses and permits authorizing the importation, exportation, production, testing, packaging, labeling, sending, delivery, transportation, sale, possession or disposal of cannabis and cannabis products. The Cannabis Act would authorize Canadian provinces and territories to regulate the distribution and retail sale of cannabis within their jurisdiction